Corrigendum: CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients(Scientific Reports (2016) 6(20070) DOI: 10.1038/srep20070);CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Su, Shu ^a   Hu, Bian ^b   Shao, Jie ^a   Shen, Bin ^c   Du, Juan ^a   Du, Yinan ^b   Zhou, Jiankui ^b   Yu, Lixia ^a   Zhang, Lianru ^a   Chen, Fangjun ^a   Sha, Huizi ^a   Cheng, Lei ^a   Meng, Fanyan ^a   Zou, Zhengyun ^a   Huang, Xingxu ^b,d   Liu, Baorui ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

^d SHANGHAITECH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GUIDE RNA; PROGRAMMED DEATH 1 RECEPTOR;

BIOSYNTHESIS; CELL CULTURE; CRISPR CAS SYSTEM; CYTOTOXICITY; DEFICIENCY; GENE EDITING; GENE INACTIVATION; GENE LOCUS; GENE ORDER; GENE TARGETING; GENE TRANSFER; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; NEOPLASM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHENOTYPE; T LYMPHOCYTE SUBPOPULATION;

BASE SEQUENCE; CELLS, CULTURED; CRISPR-CAS SYSTEMS; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; GENE EDITING; GENE KNOCKOUT TECHNIQUES; GENE ORDER; GENE TARGETING; GENE TRANSFER TECHNIQUES; GENETIC LOCI; GENETIC VECTORS; HUMANS; LYMPHOCYTE ACTIVATION; NEOPLASMS; PHENOTYPE; PROGRAMMED CELL DEATH 1 RECEPTOR; RNA, GUIDE; T-LYMPHOCYTE SUBSETS; TRANSFECTION;

EID: 84956465589     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep40272     Document Type: Erratum

References (37)

1. Jason, J. L. & Patrick, A. O. PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma. Oncotarget. 6, 3479-3492(2015).
2. + T cell sequestration, dysfunction and deletion. Nat Med. 19, 465-472 (2013).
3. Rosenberg, S. A., Yang, J. C. & Restifo, N. P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909 (2004).
4. Morse, M. A., Chui, S., Hobeika, A., Lyerly, H. K. & Clay, T. Recent developments in therapeutic cancer vaccines. Nat. Clin. Pract. Oncol. 2, 108-13 (2005).
5. Rubio, V. et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat. Med. 9, 1377-82 (2003).
6. Stuge, T. B. et al. Diversity and recognition efficiency of T cell responses to cancer. PLoS Med. 1, 149-160 (2004).
7. Kohrt, H. E., Shu, C. T., Stuge, T. B., Holmes, S. P. & Weber, J. Rapid assessment of recognition efficiency and functional capacity of antigen-specific T-cell responses. J. Immunother. 28, 297-305 (2005).
8. Keir, M. E., Butte M. J., Freeman G. J. & Sharpe A. H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677-704 (2008).
9. Punkosdy, G. A. et al. Regulatory T-cell expansion during chronic viral infection is dependent on endogenous retroviral superantigens. Proc. Natl. Acad. Sci. USA. 108, 3677-3682 (2011).
10. + CD25 (Hi) regulatory T cells. Int. Immunol. 21, 1065-1077 (2009).
11. Suzanne, L. T. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
12. Pen, J. J. et al. Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells. Gene Therapy. 21, 262-271 (2014).
13. Lloyd, A., Vickery, O. N. & Laugel, B. Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies. Frontier in Immunology. 4, 1-7 (2013).
14. Provasi, E. et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat. Med. 18, 807-815 (2012).
15. Holkers, M. et al. Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells. Nucleic Acids Res. 41, e63 (2012)
16. Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 337, 816-821 (2012).
17. Mali, P., Esvelt, K. M. & Church, G. M. Cas9 as a versatile tool for engineering biology. Nat. Methods. 10, 957-963 (2013).
18. Li, W., Teng, F., Li, T. & Zhou, Q. Simultaneous generation and germline transmission of multiple gene mutations in rat using CRISPR-Cas systems. Nat. Biotechnol. 31, 684-686 (2013).
19. Shen, B. et al. Generation of gene-modified mice via Cas9/RNA-mediated gene targeting. Cell Res. 23, 720-723 (2013).
20. Ma, Y. et al. Generating rats with conditional alleles using CRISPR/ Cas9. Cell Res. 24, 122-125 (2014).
21. Niu, Y. et al. Generation of gene-modified Cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell. 156, 1-8 (2014).
22. Shen, B. et al. Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. Nat. Methods. 11, 399-402 (2014).
23. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer. 12, 252-264 (2012).
24. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2014).
25. Berger, R. et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 14, 3044-3051 (2008).
26. Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012).
27. Raymond, M. et al. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigenspecific CTLs. International Immunology. 10, 1223-1234 (2007).
28. Borkner, L. et al. RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells. Cancer Immunol Immunother. 59, 1173-1183 (2010).
29. Iwamura1, K. et al. siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions. Gene Therapy. 19, 959-966 (2012).
30. Xiao, J. T. et al. T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo. J. Biomed Res. 28, 468-475 (2014).
31. John, L. B. et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cell. Clin. Cancer Res. 9, 5636-5646 (2013).
32. Chicaybam, L., Sodre, A. L., Curzio, B. A. & Bonamino, M. H. An efficient low cost method for gene transfer to T lymphocytes. Plos One. 8, e60298 (2013).
33. Singh, H. et al. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using sleeping beauty system and artificial antigen presenting cells. Plos One. 8, e64138 (2013).
34. Christian, B. et al. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int. J. Cancer. 119, 317-327 (2006)
35. Gregory L. & Beatty Y. P. Regulation of Tumor Growth by IFN- in Cancer Immunotherapy. Immunologic Research. 24, 201-210(2001).
36. Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 515, 568-571 (2014).
37. Dovedi, S. J. et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 74, 5458-68 (2014).